Six platforms across the Public Health Institute of Georgia network published eight items on 5–6 October 2026, spanning drug pricing policy, cognitive health research, professional education, labour economics, and supplement safety. The range reflects the network’s dual focus on clinical practice and broader public health intelligence.
GMJ News
- Medicare Proposes Fresh Cuts to Hospital 340B Drug Discount Program — Medicare has put forward new reductions to payment rates for drugs dispensed under the 340B programme, continuing regulatory scrutiny of the scheme’s cost implications.
- A 10-Second Daily Finger Exercise May Support Cognitive Function, New Research Suggests — Preliminary findings indicate that a brief daily motor task may benefit brain health in older adults through motor-cognitive coupling, though researchers caution the evidence remains early-stage.
GMJ Academy
- Gastroenterology and Endoscopy Safety Standards [AMB-22] — This course addresses high-frequency preventable events in ambulatory gastroenterology, including endoscope reprocessing failures, unmonitored sedation, and lost pathology specimens.
- Program Design and Individualization [FW-05] — Fitness professionals are guided through the FITT-VP framework to move beyond generic exercise templates and build programmes that reduce member risk and facility liability.
- Pre-Participation Screening and Risk Assessment [FW-01] — The course establishes systematic intake procedures to close the screening gaps that underlie cardiac incidents, missed diagnoses, and legal exposure in fitness settings.
Georgian Institute of Labour Studies (GILS)
- Flood-Driven Employment Shocks in Nepal: Supply-Chain and Informal-Work Lessons for Georgia — Drawing on an ILO assessment of the 2026 Nepal floods, this analysis identifies labour-market vulnerabilities in supply chains and the informal sector that carry transferable lessons for Georgia’s economic planners.
Sheni Labs
- LUZE Fit Intensity Weight-Loss Supplement Contains Hidden Controlled Substance Sibutramine — The US FDA has advised consumers to avoid LUZE Fit Intensity after laboratory testing confirmed the product contains undisclosed sibutramine, a controlled substance withdrawn from most markets due to cardiovascular risks.
The full live feed for all network publications is available at publichealth.ge/network.
Compiled by the PHIG Network Desk from items published on the platforms of the network in the previous day, with human editorial oversight under Policy 27 and Policy 50. Sources are linked; nothing is added beyond what the platforms published. Corrections: info@accreditation.ge.
PHIG
Public Health Institute of Georgia
